Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Rare cancers and the difficulties in making clinical decisions

Dr Paolo Casali - National Tumour Institute, Milan, Italy

Rare cancers and the difficulties in making clinical decisions ( Dr Paolo Casali - National Tumour Institute, Milan, Italy )

Anamorelin improves appetite and body mass in non-small cell lung cancer with...

Dr David Currow - Flinders University, Adelaide, Australia

Anamorelin improves appetite and body mass in non-small cell lung cancer with cancer anorexia-cachexia ( Dr David Currow - Flinders University, Adelaide, Australia )

Rolapitant reduces nausea and vomiting associated with cisplatin-based...

Dr Bernardo Leon Rapoport - The Medical Oncology Centre, Johannesburg, South...

Rolapitant reduces nausea and vomiting associated with cisplatin-based chemotherapy ( Dr Bernardo Leon Rapoport - The Medical Oncology Centre, Johannesburg, South Africa )

New drug anamorelin shows improvement in appetite and body mass in non-small...

Prof David Currow - Flinders University, Adelaide, Australia

New drug anamorelin shows improvement in appetite and body mass in non-small cell lung cancer with cancer anorexia-cachexia ( Prof David Currow - Flinders University, Adelaide, Australia )

Second-line afatinib significantly improves PFS in metastatic head and neck...

Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium

Second-line afatinib significantly improves PFS in metastatic head and neck cancer ( Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium )

Optimising metastic renal cell carcinoma (mRCC): Treatment lessons from the...

Dr Thomas Hutson - Baylor University Medical Center, Dallas, USA

Optimising metastic renal cell carcinoma (mRCC): Treatment lessons from the real world: Introduction ( Dr Thomas Hutson - Baylor University Medical Center, Dallas, USA )

Additional treatment options impact first-line treatment of mRCC: No

Prof Stéphan Oudard - Hôpital Européen Georges Pompidou, Paris, France

Additional treatment options impact first-line treatment of mRCC: No ( Prof Stéphan Oudard - Hôpital Européen Georges Pompidou, Paris, France )

Discussion: Additional treatment options impact first-line treatment of mRCC

Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán

Discussion: Additional treatment options impact first-line treatment of mRCC ( Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán )

Additional treatment options impact first-line treatment of mRCC: Yes

Prof Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium

Additional treatment options impact first-line treatment of mRCC: Yes ( Prof Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium )

What have we learned? Expert perspectives

Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán

What have we learned? Expert perspectives ( Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán )

From clinical trial to clinical practice: Evidence from the real world

Dr Ignacio Durán - Associate Director of Clinical Research at START Madrid...

From clinical trial to clinical practice: Evidence from the real world ( Dr Ignacio Durán - Associate Director of Clinical Research at START Madrid, Madrid, Spain )

Navigating current treatment options for HER2-positive MBC: Patient journey 1

Dr Rupert Bartsch - Medical University of Vienna, Vienna, Austria

Navigating current treatment options for HER2-positive MBC: Patient journey 1 ( Dr Rupert Bartsch - Medical University of Vienna, Vienna, Austria )

More from ecancer